Shire deal makes strategic sense: Pro

Shire remains a sound and attractive purchase for AbbVie at this valuation, as it is a partially tax-motivated purchase, says Raghuram Selvaraju, head of healthcare equity research at Aegis Capital. He added that Abbvie could potentially migrate its tax burden to the U.K. as a result of the deal.